Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

Open access
Read, Robert C, Baxter, David, Chadwick, David R, Faust, Saul N, Finn, Adam, Gordon, Stephen B, Heath, Paul T, Lewis, David J M, Pollard, Andrew J, Turner, David P J, Bazaz, Rohit, Ganguli, Amitava, Havelock, Tom, Neal, Keith R, Okike, Ifeanyichukwu O, Morales-Aza, Begonia, Patel, Kamlesh, Snape, Matthew D, Williams, John, Gilchrist, Stefanie, Gray, Steve J, Maiden, Martin C J, Toneatto, Daniela, Wang, Huajun, McCarthy, Maggie, Dull, Peter M, Borrow, Ray·2014·The Lancet

Abstract

BACKGROUND Meningococcal conjugate vaccines protect individuals directly, but can also confer herd protection by interrupting carriage transmission. We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates in 18-24-year-olds. METHODS In this phase 3, observer-blind, randomised controlled trial, university students aged 18-24 years from ten sites in England were randomly assigned (1:1:1, block size of three) to receive two doses 1 month apart of Japanese Encephalitis vaccine (controls), 4CMenB, or one dose of MenACWY-CRM then placebo. Participants were randomised with a validated computer-generated random allocation list. Participants and outcome-assessors were masked to the treatment group. Meningococci were isolated from oropharyngeal swabs collected before vaccination and at five scheduled intervals over 1 year. Primary outcomes were cross-sectional carriage 1 month after each vaccine course. Secondary outcomes included comparisons of carriage at any timepoint after primary analysis until study termination. Reactogenicity and adverse events were monitored throughout the study. Analysis was done on the modified intention-to-treat population, which included all enrolled participants who received a study vaccination and provided at least one assessable swab after baseline. This trial is registered with ClinicalTrials.gov, registration number NCT01214850. FINDINGS Between Sept 21 and Dec 21, 2010, 2954 participants were randomly assigned (987 assigned to control [984 analysed], 979 assigned to 4CMenB [974 analysed], 988 assigned to MenACWY-CRM [983 analysed]); 33% of the 4CMenB group, 34% of the MenACWY-CRM group, and 31% of the control group were positive for meningococcal carriage at study entry. By 1 month, there was no significant difference in carriage between controls and 4CMenB (odds ratio 1·2, 95% CI 0·8-1·7) or MenACWY-CRM (0·9, [0·6-1·3]) groups. From 3 months after dose two, 4CMenB vaccination resulted in significantly lower carriage of any meningococcal strain (18·2% [95% CI 3·4-30·8] carriage reduction), capsular groups BCWY (26·6% [10·5-39·9] carriage reduction), capsular groups CWY (29·6% [8·1-46·0] carriage reduction), and serogroups CWY (28·5% [2·8-47·5] carriage reduction) compared with control vaccination. Significantly lower carriage rates were also noted in the MenACWY-CRM group compared with controls: 39·0% (95% CI 17·3-55·0) carriage reduction for serogroup Y and 36·2% (15·6-51·7) carriage reduction for serogroup CWY. Study vaccines were generally well tolerated, with increased rates of transient local injection pain and myalgia in the 4CMenB group. No safety concerns were identified. INTERPRETATION Although we detected no significant difference between groups at 1 month after vaccine course, MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates during 12 months after vaccination and therefore might affect transmission when widely implemented. FUNDING Novartis Vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60842-4

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 280

Metadata

Authors
Read, R. C., Baxter, D., Chadwick, D. R., Faust, S. N., Finn, A., Gordon, S. B., Heath, P. T., Lewis, D. J. M., Pollard, A. J., Turner, D. P. J., Bazaz, R., Ganguli, A., Havelock, T., Neal, K. R., Okike, I. O., Morales-Aza, B., Patel, K., Snape, M. D., Williams, J., Gilchrist, S., Gray, S. J., Maiden, M. C. J., Toneatto, D., Wang, H., McCarthy, M., Dull, P. M., & Borrow, R.
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-12
Volume
384
Issue
9960
Pages
2123-2131
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2097124616
Cited by
280
References
29
FWCI
27.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. https://app.cochat.ai/papers/10.1016/s0140-6736(14)60842-4
The paper
Read, R. C., Baxter, D., Chadwick, D. R., Faust, S. N., Finn, A., Gordon, S. B., Heath, P. T., Lewis, D. J. M., Pollard, A. J., Turner, D. P. J., Bazaz, R., Ganguli, A., Havelock, T., Neal, K. R., Okike, I. O., Morales-Aza, B., Patel, K., Snape, M. D., Williams, J., . . . Borrow, R. (2014). Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. The Lancet. https://doi.org/10.1016/s0140-6736(14)60842-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.